KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Long-Term Investments (2018 - 2019)

Esperion Therapeutics (ESPR) has disclosed Long-Term Investments for 2 consecutive years, with $22.1 million as the latest value for Q1 2019.

  • For the quarter ending Q1 2019, Long-Term Investments fell 47.9% year-over-year to $22.1 million, compared with a TTM value of $22.1 million through Mar 2019, down 47.9%, and an annual FY2018 reading of $243000.0, changed N/A over the prior year.
  • Long-Term Investments was $22.1 million for Q1 2019 at Esperion Therapeutics, up from $243000.0 in the prior quarter.
  • Across five years, Long-Term Investments topped out at $42.4 million in Q1 2018 and bottomed at $243000.0 in Q4 2018.